Predictors of Patients Receiving No Medication for Treatment of Eosinophilic Esophagitis in the United States: Data from the TARGET-EGIDS Cohort

Eosinophilic esophagitis is increasingly recognized and treatable, yet a subset of patients receive no pharmacologic therapy after diagnosis. The real-world predictors of remaining untreated—including demographic, clinical, and practice-setting factors—had not been characterized in a large US EoE registry.

The TARGET-EGIDs registry was analyzed to identify predictors of no recorded pharmacologic therapy among 921 newly diagnosed EoE patients, using logistic regression to characterize the patient and provider factors associated with remaining untreated.

Establishing that approximately 1 in 10 newly diagnosed EoE patients receives no medication—and that older age and absence of complications predict no treatment—identifies a real-world care gap and provides the evidence base for EoE prescriber education and access programs for novel EoE therapies.

EoE treatment gap characterization for prescriber education and novel therapy access strategy, Real-world predictors of no pharmacologic treatment in EoE for drug development planning, Evidence base for EoE care quality improvement and patient advocacy programs